A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

Timeline

Start

2022-02-04

Primary completion

2029-04-20

Completion

2029-04-20

Drugs

Indications